Latest News and Press Releases

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and...

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off...

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and...

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid...

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progressionTreatment-free interval...

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million ...

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the...

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive...